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Abstract
Purpose: Dry eye disease affects women twice as often as men, but there is little information on whether dry eye
treatments, treatment satisfaction, or the impact of dry eye disease on patients’ lives and vision might differ by sex.
Design: Questionnaire survey of 4000 participants in the Women’s Health Study and the Physicians’ Health Studies I
and II with a prior report of a diagnosis of DED.
Methods: Among participants who re-confirmed a diagnosis of dry eye disease, we assessed symptoms, treatments,
patient satisfaction and impact of dry eye disease, and analyzed differences between men and women using
regression models.
Results: The final study population consisted of 1,518 women (mean age 70.7 years) and 581 men (mean age 76.7
years), with a mean reported duration of dry eye disease of 10.5 years and 10.1 years, respectively. The frequency
and severity of dry eye disease symptoms were higher among women (each P<0.0001), and women reported a
greater impact on everyday activities (P<0.0001). Women were more likely to use artificial tears (P<0.0001) use them
more often (P<0.0001), and to use Restasis® (P<0.0001), omega-3 fatty acids (P=0.0006), and have punctal
occlusion (P=0.005). Women spent more money per month on dry eye treatments (P<0.0001), but reported greater
dissatisfaction with treatment side effects (P=0.001), and the amount of time before treatments started working
(P=0.03).
Conclusions: These data show that dry eye disease is generally experienced as being more severe among women,
having a greater impact on their self-assessed well-being.
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Introduction
Dry eye disease (DED) is an important public health problem
characterized by a deficiency in the quantity and/or quality of
tears, an unstable tear film, ocular surface damage, and
bothersome symptoms such as ocular irritation, dryness,
fatigue, and fluctuating visual disturbances. It results in
increased risk of ocular surface infections and the bothersome
symptoms frequently interfere with activities such as reading,
working on a computer, and driving a car [1-4]. Studies over
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the past decade have identified older age, female sex, reduced
androgen levels, exogenous estrogen use, imbalances in the
dietary intake of essential fatty acids, certain antihypertensive
medications, and antidepressant medications as risk factors for
dry eye disease (DED) [2,5-7]. Large-scale studies of
participants’ in the Women’s Health Study (WHS) and
Physicians’ Health Studies (PHS) estimated that 3.25 million
US women, and 1.68 million men aged 50 and older are
affected with DED [7,8]. The prevalence of DED is higher in
several Asian populations, ranging from 21% to 52.4% [9-14].
Although DED is now known to be more common in women
[2,7,8], there is little information on whether the severity of
DED, its impact on patients’ lives and vision, and how patients
are treated may be different for women versus men. This study
was undertaken to provide information on such factors.
Design and Methods
Study Subjects
Subjects for this study came from two large national
longitudinal studies of healthcare professionals in the US: the
Women’s Health Study (WHS) [15] and the Physicians’ Health
Studies (PHS) I and II [16,17].
The WHS was a randomized, double-blind, placebo-
controlled trial conducted among 39,876 US female health care
professionals that was undertaken to assess the benefits and
risks of low-dose aspirin and vitamin E in the primary
prevention of cardiovascular disease and cancer. The original
PHS (PHS I) was a randomized, double-blind, placebo-
controlled trial to test the effects of low-dose aspirin and beta-
carotene in the primary prevention of cardiovascular disease
and cancer among 22,071 US male physicians. The second
PHS (PHS II) is a randomized, double-blind, placebo-controlled
factorial trial of alternate day beta-carotene, alternate day
vitamin E, daily vitamin C, and a daily multivitamin in the
prevention of cardiovascular disease, total and prostate cancer,
and age-related eye diseases (cataract and macular
degeneration) among 14,641 US male physicians aged 55
years and older, including 7,641 participants from the original
PHS and 7,000 newly recruited male physicians. The
remaining PHS I participants who elected not to enroll in PHS II
continue to be followed by annual questionnaires. The WHS,
PHS I, and PHS II are conducted by mail. The active treatment
phase has ended for both the WHS and PHS I, but
observational follow-up of these cohorts is ongoing. Because of
their training in medicine or other areas of healthcare,
participants have reliably reported specific details about their
health. Participants have received questionnaires every year
on which they reported their compliance with study regimens
and any side effects, as well as recorded a number of health-
related exposures and any health outcomes experienced over
the previous year. We previously assessed diagnoses of DED
and DED symptoms using a short questionnaire among
participants of WHS (aged ≥49) and PHS I and II (aged ≥55)
[7,8,18]. Of the participants who reported a diagnosis of DED
or severe dry eye symptoms in the above studies [4-8], 4000
participants were selected and sent an expanded questionnaire
to assess DED symptoms, co-morbid conditions, treatments,
risk factors, and disease impact. We selected participants who
had previously reported a diagnosis of DED starting with the
cases with the longest duration of disease in order to achieve a
study population of approximately 2,500 female participants
and 1,500 male participants. This report includes only the
subset of participants who confirmed in the present study their
prior report of having a diagnosis of DED. The method for
identifying cases of DED was previously validated and shown
to accurately identify cases of DED diagnosed by standard
clinical tests [17].
The WHS, PHS I and II, and dry eye ancillary study was
approved by the Human Subjects Committee at Brigham and
Women’s Hospital, and all subjects gave written informed
consent.
Measurements
Characteristics of the study participants.  The authors
collected data on the demographic characteristics of study
participants from available questionnaire data in each cohort.
Data included participant age, sex, self-reported race/ethnicity,
professional qualification, and highest education level.
Information on the date of diagnosis of dry eye was also
obtained from study participants, and was used to calculate the
duration of DED as of January 2011.
DED symptom severity, impact on daily activities.  We
administered a supplementary questionnaire to all participants
selected for participation in this study. The questionnaire
included a number of questions concerning symptoms
associated with DED, including 1) The Ocular Surface Disease
Index (OSDI, ©1995 Allergan, Inc) [19], and 2) The Symptom
Assessment in Dry Eye (SANDE) [20]. The OSDI consists of 12
questions to assess ocular symptoms (the Ocular Symptoms
subscale), their impact on patient vision-related functioning
(Vision Related Function subscale), and environmental factors
triggering the symptoms (Environmental Triggers subscale).
The three subscales and an overall OSDI Total score were
scored according to the user manual, each with a 100-point
scale ranging from ‘None’ to ‘Most severe’. Based on the
recommended cutoffs for OSDI Total score, we grouped the
subjects into mild, moderate or severe (OSDI Total score =
13-22, 23-32, or 33 and higher). The SANDE is a simple dry
eye instrument containing two items measuring the frequency
and severity of symptoms, each was assessed on a 100 mm
visual analog scale (VAS) ranging from ‘Rarely/Very mild’ to ‘All
the time/Very severe’ and scored from 0 to 100, from which a
SANDE Total score (also ranging from 0 to 100) was calculated
as the square-root of the product of the two item scores [20].
Based on the SANDE total score, we grouped the subjects into
three categories: Mild (<40), Moderate (40-50), or Severe
(>50).
In addition to the OSDI and SANDE, we also included a
question on fluctuating/unstable vision, ability to perform the
participant’s work/profession, as well as a series of questions
regarding feelings of calm/peacefulness, energy level, feeling
downhearted and depressed, and interference with social
activities. Participants were also asked to assess the overall
degree to which eye symptoms limited daily activities by using
a 10-point scale ranging from ‘Not at all’ to ‘Severely’.
Sex Differences in Dry Eye Disease
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DED treatments and satisfaction with DED treatment.  A
comprehensive list of DED treatments was provided and
participants were asked to check selected types of dry eye
treatments they used. Level 2 or higher treatments were
defined according to the recent report of the Dry Eye Workshop
(DEWS) [3]. We also asked about the amount of money
participants spent each month on dry eye treatments.
We measured satisfaction with DED treatment using a series
of 8 questions on the ability of treatments to relieve symptoms,
time it takes for treatments to start working, length of symptom
relief, ease of use, convenience, side-effects, and overall
treatment satisfaction. Responses were recorded on a 5-point
scale ranging from ‘Extremely satisfied’ to ‘Extremely
dissatisfied’.
Statistical Analysis
We compared data from the dry eye questionnaire between
respondents from the WHS (all women), and the PHS I and
PHS II (all men). To test for differences between men and
women, we used t-tests for continuous variables (current age,
duration of DED, OSDI and SANDE scores), Chi-square tests
for dichotomous variables, and Cochran-Armitage Trend tests
for ordinal variables. To adjust for age differences between the
cohorts, we used least square regression models for
continuous variables, and constructed multivariable logistic
regression models for each dichotomous factor of interest, and
tested whether sex was associated with that factor after
controlling for current age as a continuous variable. For factors
with >2 levels of ordered responses (ordinal variables), we fit
proportional odds models to test for associations with sex,
while simultaneously adjusting for possible associations with
age. For these models, we initially fit models using all original
response levels and tested the proportional odds assumption
using the score test. If the proportional odds assumption was
violated, we fit a new model based on collapsing response
levels from 5 or more to 3 and re-tested the proportional odds
assumption. From each model, we obtained odds ratios (OR)
and their corresponding ninety-five percent confidence intervals
(CI) for the association of age and sex with each factor.
Results
Demographic and Clinical Characteristics of the
Respondents
Of the 4000 WHS and PHS participants to whom we mailed
the survey questionnaire, 3390 returned the questionnaire
(85% response rate). Of the 3390 respondents, 2099 (62%)
had previously reported a clinical diagnosis of dry eye and
confirmed a diagnosis of dry eye on the current questionnaire.
This constituted the dry eye sample for this paper.
Of the 2099 respondents who confirmed a diagnosis of dry
eye, 581 (28%) were men and 1518 (72%) were women. About
91% men and 96% women were white. By design of the source
studies, all men were physicians with MD or equivalent
degrees, whereas the women were all health professionals,
including three quarters who were registered nurses. Women
were 6 years younger on average (mean age at diagnosis=60
y) compared to men (mean age at diagnosis=66 y) at the time
they were first diagnosed with DED, but had similar duration of
DED at the time of the survey (Table 1). There were no
differences between women and men in self-reported general
health (p=0.74) and general eye health (p=0.48).
Table 1. Characteristics of the study participants.
 Men Women P value
Sample size (N) 581 1518  
Race (%)   <0.0001
White 91.1 96.0  
Hispanic  1.9  1.4  
African American/Black  0.9  1.2  
Asian  4.7  1.0  
Other  1.5  0.4  
Professional qualification (%)   <0.0001
MD or equivalent 100  2.2  
RN 0 77.1  
LPN/LVN 0 13.0  
Other 0  7.6  
Highest educational level   <0.0001
Licensed/Registered nurse training 0 55.5  
BS nursing 0 24.7  
Master’s degree 0 14.9  
MD/doctoral degree 100  4.9  
Current Age (years; mean & SD) 76.7 (8.6) 70.7 (6.5) <0.0001
Age at Diagnosis of DED (years; mean & SD) 66.1 (12.6) 60.0 (11.0) <0.0001
Duration of dry eye (years; mean & SD) 10.1 (9.2) 10.5 (8.9) 0.42
doi: 10.1371/journal.pone.0076121.t001
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DED Symptom Severity, Impact on Daily Activities
As measured by OSDI subscale and overall scores (each
P<0.0001), or by SANDE item and overall scores (each
P<0.0001), women reported significantly higher levels of dry
eye symptom severity (Table 2). When categorized by the
OSDI overall score, 33.6% of women and 15.6% of men
reported severe dry eye symptoms, with mean scores of 26.8
among women versus 18.2 among men. Using the SANDE
overall score, dry eye symptoms of 39.1% of women and
17.9% of men were classified as severe and women reported a
mean score of 42.3 compared with 27.2 among men. Overall,
women also reported a significantly greater impact and worse
quality of life from their disease (Table 3 and Figure 1). For
example, women with DED reported significantly greater
problems with vision (blurred vision, poor vision, and
fluctuating/unstable vision), reading, driving at night, watching
television, and working on a computer compared to men with
DED. Women with DED were less likely than men with DED to
report feeling calm and peaceful or having a lot of energy, and
more likely to report feeling depressed.
DED Treatments and Satisfaction with DED Treatment
Of the DED treatments we inquired about, the top three
Level 1 treatments used were artificial tears (used by 82.8%
women and 62.6% men), lubricating eye ointments (used by
19.2% women and 11.7% men), and hot compresses (used by
14.3% women and 10.7% men). The top three Level 2 and
higher levels treatments were oral omega-3 fatty acids
supplements (used by 18.6% women and 9.6% men), punctum
plugs (used by 15.0% women and 9.1% men) and cyclosporine
eye drops (Restasis®, used by 13.4% women and 6.4% men)
(Figure 2). When comparing between women and men, and
adjusting for age, we found significantly more women were
using each of these 6 treatments (Table 4). Consistent with
this, we also observed that women spent more money, on
average, per month on dry eye treatments (P<0.0001).
In analyses of patient satisfaction with DED treatments,
respondents in general were satisfied with the treatments’
ability to relieve symptoms, the amount of time for the
treatments to work, and their ease of use and convenience, but
less satisfied with the treatments’ duration of effect (how long
treatments relieved symptoms) (Figure 3). When comparing
women with men and adjusting for age in proportional odds
models across the 5 categories of response (ranging from
extremely dissatisfied to extremely satisfied), women
expressed about the same level of general satisfaction with
treatments, except for reporting greater dissatisfaction with
treatment side effects, and the time it takes for the treatment to
start working (Table 5). The proportional odds assumption was
violated in 3 of these models, for the ability of the treatment to
relieve symptoms, how long the treatment relieves symptoms,
and the convenience of treatment use as instructed. In
alternative models in which we collapsed responses into 3
categories of somewhat or extremely dissatisfied, neither
satisfied nor dissatisfied, and somewhat or extremely satisfied,
the proportional odds assumption was not violated for the
model for convenience of treatment use as instructed, for which
the model showed that women were significantly less likely to
be dissatisfied with this aspect of their dry eye treatment
(OR=0.74, CI=0.58-0.95).
Discussion
Previous analyses from these cohorts demonstrated a
significantly higher prevalence of DED among women
compared to men in the US [7,8]. In the present study, we
extend those observations to show that women are not only
affected more often, but are also diagnosed at an average of 6
years younger age. Recent estimates from the United Nations
Table 2. Current level of DED symptoms reported by men and women with diagnosed DED.
 Women Men P value
 Mean (SD) Mean (SD)  
DED symptoms based on OSDI*†    
Ocular Symptoms subscale 29.0 (21.6) 18.5 (18.3) <0.0001
Vision Related Function subscale 22.0 (19.9) 17.3 (19.3) <0.0001
Environmental Triggers subscale 35.4 (29.3) 21.2 (23.7) <0.0001
Overall score of OSDI 26.8 (18.7) 18.2 (16.4) <0.0001
DED symptoms based on SANDE*‡    
Frequency 48.4 (28.5) 32.4 (28.1) <0.0001
Severity 39.4 (27.4) 24.9 (23.0) <0.0001
Overall Score 42.3 (26.8) 27.2 (23.7) <0.0001
How much dry eye symptoms limited daily activities§ 3.2 (2.2) 2.6 (1.8) <0.0001
*. P-values are from linear regression models adjusted for age. Age was significantly inversely associated only with the OSDI Environmental Triggers subscale (P=0.0002)
† OSDI=The Ocular Surface Disease Index, a validated questionnaire to measure symptoms of DED. Scores range from 0 (no symptoms) to 100 (maximum symptoms).
‡. SANDE=The Symptom Assessment in Dry Eye questionnaire, a validated visual analogue scale to assess ocular surface discomfort in DED. Scores range from 0 to 100
with higher scores indicating worse symptoms.
§. A single question from our questionnaire; scores ranged from 0=Not at all - 10=Severely. This P-value is from a proportional odds logistic regression model adjusted for
age.
doi: 10.1371/journal.pone.0076121.t002
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Department of Economic and Social Affairs, showed that the
average life expectancy in the US for women is 5 years longer
than that of men. Therefore, given its chronic nature, an earlier
diagnosis of DED might result in a longer duration of suffering
with this disease for women. Our data also show that women’s
self-reported experience with DED tends to be more severe, as
they report higher levels of dry eye symptoms, greater use of
dry eye treatments, and a greater adverse impact of DED on
everyday activities including reading, driving, watching TV and
working with a computer. Although there were no significant
differences in reported overall levels of satisfaction with regard
to dry eye treatments after controlling for age-related
differences (younger individuals reported less satisfaction),
women were more dissatisfied with treatment side effects, and
the amount of time before treatments started working.
The study population of women and men with diagnosed dry
eye included participants with few symptoms to those with
severe dry eye symptoms. The percentage of women who
could be categorized as having severe symptoms was about
double that of men. Consistent with this, mean total OSDI and
SANDE scores as well as all OSDI subscale scores were all
higher among women. The cornea and ocular surface are richly
innervated with sensory neurons that respond to a variety of
stimuli, causing sensations of ocular surface irritation as well as
stimulation of mechanisms designed to protect the ocular
surface system. In dry eye, the sensory nerves may be
damaged due to chronic inflammation or other mechanisms,
giving rise to dry eye symptoms and also possibly contributing
to disease chronicity. Thus, dry eye can be considered a type
of chronic pain condition with much of its public health impact
due to its symptoms. In that light, data from the present study
are consistent with the general observation that, compared to
men, women tend to report more intense, frequent, and longer
duration pain [21]. It has been widely accepted that hormonal
alterations such as administration and withdrawal of estrogens
can increase risk for pain [22]. Recent clinical and
epidemiologic findings also indicate that women are at
increased risk for many choronic pain conditions, and women
tend to report higher levels of acute procedural pain [22]. Prior
meta-analyses also showed that there are sex differences in
experimental pain sensitivity [23]. It is thought that such sex-
related differences in pain are likely due to the interaction of
biological differences between men and women (e.g. genetic or
hormonal factors) with psychological and socio-cultural factors
[22]. Future studies might focus on determining the underlying
causes of the greater severity DED symptoms in women.
Previous studies have identified a number of functional
consequences of dry eye including difficulties with tasks
requiring sustained visual attention such as reading, driving at
night, and using a computer [4]. Results from the present study
indicate that women with DED report experiencing such
limitations more frequently than men. Specifically, women
reported a higher frequency of experiencing limitations of daily
activities overall and specifically more frequent problems with
reading, driving at night, working with a computer or bank
machine, and watching TV compared to men. Women also
reported more frequent blurred vision, poor vision, and
fluctuating or unstable vision. In addition to these vision-related
impacts, women with DED were less likely to feel calm and
peaceful, less likely to have a lot of energy, and more likely to
report anxiety, and to feel depressed.
Table 3. Impact of DED on quality of life measures among women versus men with diagnosed DED.
 OR (95% CI)* P value*
How much dry eye symptoms limited daily activities§ 1.50 (1.24-1.80) <0.0001
Experienced the following during the past 4 weeks †   
Blurred vision 1.31 (1.07-1.60) 0.01
Poor vision 1.40 (1.14-1.72) 0.002
Fluctuating/unstable vision 1.27 (1.02-1.58) 0.03
Eye problem limited the following during the past 4 weeks †   
Reading 1.34 (1.10-1.64) 0.004
Driving during the day 1.27 (0.98-1.65) 0.08
Driving at night 2.76 (2.23-3.42) <0.0001
Working with computer or bank machine (ATM) 1.65 (1.32-2.06) <0.0001
Watching T.V. 1.50 (1.20-1.88) 0.0005
Your work/profession 1.35 (0.97-1.83) 0.05
How much of the time during the past 4 weeks †   
have you felt calm and peaceful? 0.62 (0.45-0.85) 0.003
did you have a lot of energy? 0.63 (0.50-0.79) <0.0001
have you felt depressed? 1.28 (1.04-1.57) 0.02
have your eye problem interfered with your social activities? 1.22 (0.86-1.73) 0.26
*. The odds ratio (OR) indicates the ratio of women’s odds over men’s, each estimated from a separate proportional odds logistic regression model adjusted for age. None of
the models violated the proportional odds assumption.
§. Scores ranged from 0 (=Not at all) to 10 (=Severely).
† Response levels collapsed to 3 categories (None of the time, Some of the time, or Half/Most/All of the time)
doi: 10.1371/journal.pone.0076121.t003
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Figure 1.  Impact of DED on quality of life measures, by sex.  The chart depicts the percentage of women (N=1518) and men
(N=581) with diagnosed dry eye for each category of response for questions related to quality of life.
doi: 10.1371/journal.pone.0076121.g001
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Figure 2.  Reported use of DED treatments, by sex.  The chart depicts the percentage of subjects reporting use of a number of
available dry eye treatments, separately for women (N=1518) and men (N=581) with diagnosed dry eye.
doi: 10.1371/journal.pone.0076121.g002
Sex Differences in Dry Eye Disease
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A limitation of the study relates to our assessment of DED
using self-reports of clinically diagnosed dry eye and self-
reported information on its impact. However, we previously
validated our questionnaire-based method of DED assessment
and found a good balance of sensitivity and specificity versus
commonly used clinical tests for DED [18], and we limited this
analysis to respondents who confirmed their original report of
DED on the most recent questionnaire. Although it remains
possible that some of the men and women in our study may not
have DED, use of the same methodology in both cohorts
should have minimized any bias in comparisons between men
and women. There were also differences in the degree of
education and medical knowledge between the men and
women in this study, and it is possible that differences in the
degree of medical knowledge might have impacted reporting of
some items. Finally, the underlying cohorts from which the
study population was derived are not a random sample of the
US population, and exclusion criteria for these two large-scale
randomized prevention trial cohorts may have impacted the
prevalence of some factors. Comparisons between men and
women should remain valid, however, as the selection criteria
were virtually identical for the two randomized trials.
The study benefits from a large sample size and in depth
information including assessments of dry eye symptoms, co-
morbid conditions, medication use, dry eye treatments, and
measures of treatment satisfaction. There were no significant
differences in the duration of DED between the men and
women, which should minimize any differences that might arise
with longer duration of disease. We controlled for age in order
to control for possible confounding that might have arisen due
to the older age of the PHS cohort.
DED has received recognition as a common ocular problem
affecting older women more often than men, but there have
been fewer data to describe possible differences in disease
severity, impact, treatments, and treatment satisfaction
between the sexes. The present study fills some of these gaps
by characterizing a large group of men and women with DED.
The study demonstrates that women with DED are diagnosed
at a younger age, and report a higher level of symptoms,
greater use of treatments, and lower satisfaction with some
aspects of treatment compared to men. Women with DED also
reported a greater impact of DED on everyday activities. Such
findings are indicative of a greater impact of DED on quality of
life among women. These findings also indicate the impact of
DED extends beyond the eye and vision, and we hope might
encourage clinicians to seek means of managing the “whole
patient” so that the impact of DED can be minimized.
Table 4. Odds of use of DED treatments among women versus men with DED.
 OR (95% CI)* P value*
Level 1   
Artificial tear use 3.46 (2.71-4.41) <0.0001
Lubricating eye ointment 1.80 (1.33-2.43) 0.0001
Hot compresses 1.48 (1.07-2.04) 0.02
Lid scrubs 1.30 (0.90-1.88) 0.16
Humidifier 2.47 (1.59-3.83) <0.0001
Eye washes 1.01 (0.64-1.59) 0.96
Cold compresses 2.91 (1.58-5.37) 0.0006
Moisture spray/mist 8.11 (1.07-61.24) 0.04
Level 2 and higher   
Omega-3 fatty acids 1.74 (1.27-2.39) 0.0006
Punctum plugs 1.55 (1.11-2.16) 0.01
Restasis® (cyclosporine eye drops) 2.17 (1.48-3.17) <0.0001
Steroid eye drops 1.35 (0.68-2.67) 0.39
Surgery/laser for permanent punctal occlusion 1.57 (1.15-2.14) 0.005
Oral antibiotics 0.71 (0.34-1.49) 0.36
Erythromycin eye ointment 1.39 (0.60-3.22) 0.45
Moisture or "airlock" goggles 2.23 (0.46-10.68) 0.32
*. The odds ratios (OR) indicate the ratio of women’s odds over men’s, each estimated from a separate logistic regression model adjusted for age.
doi: 10.1371/journal.pone.0076121.t004
Sex Differences in Dry Eye Disease
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Figure 3.  Satisfaction with DED treatments, by sex.  The chart depicts participant satisfaction with using dry eye treatments,
separately for women (N=1518) and men (N=581) with diagnosed dry eye.
doi: 10.1371/journal.pone.0076121.g003
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Table 5. Comparison of Satisfaction with DED Treatments among Women versus Men.
 OR over 5 Categories (95% CI)* P value*
Ability of Treatment to Relieve Symptoms† 1.10 (0.89-1.35) 0.39
Amount of Time for Treatment to Work 1.27 (1.03-1.57) 0.03
How Long Treatment Relieves Symptoms† 1.03 (0.83-1.27) 0.79
Ease of Use of Treatment 1.02 (0.82-1.26) 0.89
Ease of Planning When to Use Treatment 1.01 (0.82-1.24) 0.95
Convenience of Treatment Use as Instructed† 0.87 (0.70-1.07) 0.19
Side Effects of Treatment 1.43 (1.15-1.78) 0.001
Overall Treatment of Dry Eye 1.14 (0.93-1.40) 0.22
*. The odds ratios (OR) indicate the ratio of women’s odds over men’s, each estimated from a separate proportional odds logistic regression model adjusted for age.
† The proportional odds assumption was violated in the models indicated.
doi: 10.1371/journal.pone.0076121.t005
Sex Differences in Dry Eye Disease
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e76121
Author Contributions
Conceived and designed the experiments: DAS. Performed the
experiments: DAS WGC JEB. Analyzed the data: DAS.
Contributed reagents/materials/analysis tools: DAS WGC RDS
JEB JZL. Wrote the manuscript: DAS MU JZL.
References
1. Definition and Classification Subcommittee of the International Dry Eye
WorkShop (2007) The definition and classification of dry eye disease:
report of the Definition and Classification Subcommittee of the
International Dry Eye WorkShop. Ocul Surf 5: 75-92.
2. Epidemiology Subcommittee of the International Dry Eye WorkShop
(2007) The epidemiology of dry eye disease: report of the Epidemiology
Subcommittee of the International Dry Eye WorkShop. Ocul Surf 5:
93-107.
3. Management and Therapy Subcommittee of the International Dry Eye
WorkShop (2007) Management and therapy of dry eye disease: report
of the Management and Therapy Subcommittee of the International Dry
Eye WorkShop. Ocul Surf 5: 163-178.
4. Miljanović B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of
dry eye syndrome on vision-related quality of life. Am J Ophthalmol
143: 409-415. doi:10.1016/j.ajo.2006.11.060. PubMed: 17317388.
5. Miljanović B, Trivedi KA, Dana MR, Gilbard JP, Buring JE et al. (2005)
Relation between dietary n-3 and n-6 fatty acids and clinically
diagnosed dry eye syndrome in women. Am J Clin Nutr 82: 887-893.
PubMed: 16210721.
6. Schaumberg DA, Buring JE, Sullivan DA, Dana MR (2001) Hormone
replacement therapy and dry eye syndrome. JAMA 286: 2114-2119.
doi:10.1001/jama.286.17.2114. PubMed: 11694152.
7. Schaumberg DA, Dana R, Buring JE, Sullivan DA (2009) Prevalence of
dry eye disease among US men: estimates from the Physicians’ Health
Studies. Arch Ophthalmol 127: 763-768. doi:10.1001/archophthalmol.
2009.103. PubMed: 19506195.
8. Schaumberg DA, Sullivan DA, Buring JE, Dana MR (2003) Prevalence
of dry eye syndrome among US women. Am J Ophthalmol 136:
318-326. doi:10.1016/S0002-9394(03)00218-6. PubMed: 12888056.
9. Guo B, Lu P, Chen X, Zhang W, Chen R (2010) Prevalence of dry eye
disease in Mongolians at high altitude in China: the Henan eye study.
Ophthalmic Epidemiol 17: 234-241. doi:
10.3109/09286586.2010.498659. PubMed: 20642346.
10. Lu P, Chen X, Liu X, Yu L, Kang Y et al. (2008) Dry eye syndrome in
elderly Tibetans at high altitude: a population-based study in China.
Cornea 27: 545-551. doi:10.1097/ICO.0b013e318165b1b7. PubMed:
18520503.
11. Lin PY, Tsai SY, Cheng CY, Liu JH, Chou P et al. (2003) Prevalence of
dry eye among an elderly Chinese population in Taiwan: the Shihpai
Eye Study. Ophthalmology 110: 1096-1101. doi:10.1016/
S0161-6420(03)00262-8. PubMed: 12799232.
12. Uchino M, Dogru M, Uchino Y, Fukagawa K, Shimmura S et al. (2008)
Japan Ministry of Health study on prevalence of dry eye disease among
Japanese high school students. Am J Ophthalmol 146: 925-929 e922
doi:10.1016/j.ajo.2008.06.030. PubMed: 18723141.
13. Uchino M, Schaumberg DA, Dogru M, Uchino Y, Fukagawa K et al.
(2008) Prevalence of dry eye disease among Japanese visual display
terminal users. Ophthalmology 115: 1982-1988. doi:10.1016/j.ophtha.
2008.06.022. PubMed: 18708259.
14. Lee AJ, Lee J, Saw SM, Gazzard G, Koh D et al. (2002) Prevalence
and risk factors associated with dry eye symptoms: a population based
study in Indonesia. Br J Ophthalmol 86: 1347-1351. doi:10.1136/bjo.
86.12.1347. PubMed: 12446361.
15. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE (2000)
Baseline characteristics of participants in the Women’s Health Study. J
Womens Health Gend Based Med 9: 19-27. doi:
10.1089/152460900318911. PubMed: 10718501.
16. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B et al.
(1996) Lack of effect of long-term supplementation with beta carotene
on the incidence of malignant neoplasms and cardiovascular disease.
N Engl J Med 334: 1145-1149. doi:10.1056/NEJM199605023341801.
PubMed: 8602179.
17. Christen WG, Gaziano JM, Hennekens CH (2000) Design of
Physicians’ Health Study II--a randomized trial of beta-carotene,
vitamins E and C, and multivitamins, in prevention of cancer,
cardiovascular disease, and eye disease, and review of results of
completed trials. Ann Epidemiol 10: 125-134. doi:10.1016/
S1047-2797(99)00042-3. PubMed: 10691066.
18. Gulati A, Sullivan R, Buring JE, Sullivan DA, Dana R et al. (2006)
Validation and repeatability of a short questionnaire for dry eye
syndrome. Am J Ophthalmol 142: 125-131. doi:10.1016/j.ajo.
2006.02.038. PubMed: 16815260.
19. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL
(2000) Reliability and validity of the Ocular Surface Disease Index. Arch
Ophthalmol 118: 615-621. doi:10.1001/archopht.118.5.615. PubMed:
10815152.
20. Schaumberg DA, Gulati A, Mathers WD, Clinch T, Lemp MA et al.
(2007) Development and validation of a short global dry eye symptom
index. Ocul Surf 5: 50-57. doi:10.1016/S1542-0124(12)70053-8.
PubMed: 17252166.
21. Popescu A, LeResche L, Truelove EL, Drangsholt MT (2010) Gender
differences in pain modulation by diffuse noxious inhibitory controls: a
systematic review. Pain 150: 309-318. doi:10.1016/j.pain.2010.05.013.
PubMed: 20557999.
22. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL
3rd (2009) Sex, gender, and pain: a review of recent clinical and
experimental findings. J Pain 10: 447-485. doi:10.1111/j.
1526-4637.2009.00590.x. PubMed: 19411059.
23. Riley JL 3rd, Robinson ME, Wise EA, Myers CD, Fillingim RB (1998)
Sex differences in the perception of noxious experimental stimuli: a
meta-analysis. Pain 74: 181-187. doi:10.1016/S0304-3959(97)00199-1.
PubMed: 9520232.
Sex Differences in Dry Eye Disease
PLOS ONE | www.plosone.org 11 September 2013 | Volume 8 | Issue 9 | e76121
